Oral epithelial dysplasia: Do we have a management solution? A systematic review

Advances in Oral and Maxillofacial Surgery Pub Date : 2025-03-17 DOI:10.1016/j.adoms.2025.100533

Navini Mannapperuma , Chiew Ying Chieng , Velupillai Ilankovan

{"title":"Oral epithelial dysplasia: Do we have a management solution? A systematic review","authors":"Navini Mannapperuma , Chiew Ying Chieng , Velupillai Ilankovan","doi":"10.1016/j.adoms.2025.100533","DOIUrl":null,"url":null,"abstract":"<div><div>Currently there is no definite approved guidelines over the treatment and follow-up required for patients with oral epithelial dysplasia (OED). There are ample controversies based on predicting the malignant transformation potential and deciding the management options solely based on the degree of epithelial dysplasia. The objective of this review was to identify an evidence-based management pathway for OED. The systematic review was conducted using PubMed, EMBASE using PRISMA guidelines. Following applications of inclusion and exclusion criteria, only 12 studies were included in the review. Overall, there were a wide variation in the reported recurrence rate (2.5 %–51.4 %) and the malignant transformation rate (MTR) (2.6–27 %). The degree of dysplasia was not significant in malignant transformation. The mainstay of treatment includes observation, laser ablation and excision with no concrete evidence of resolution. Therefore, there is an urgent need for a multidisciplinary conference to create a consensus for treatment pathway for OED.</div></div>","PeriodicalId":100051,"journal":{"name":"Advances in Oral and Maxillofacial Surgery","volume":"18 ","pages":"Article 100533"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Oral and Maxillofacial Surgery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667147625000202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Currently there is no definite approved guidelines over the treatment and follow-up required for patients with oral epithelial dysplasia (OED). There are ample controversies based on predicting the malignant transformation potential and deciding the management options solely based on the degree of epithelial dysplasia. The objective of this review was to identify an evidence-based management pathway for OED. The systematic review was conducted using PubMed, EMBASE using PRISMA guidelines. Following applications of inclusion and exclusion criteria, only 12 studies were included in the review. Overall, there were a wide variation in the reported recurrence rate (2.5 %–51.4 %) and the malignant transformation rate (MTR) (2.6–27 %). The degree of dysplasia was not significant in malignant transformation. The mainstay of treatment includes observation, laser ablation and excision with no concrete evidence of resolution. Therefore, there is an urgent need for a multidisciplinary conference to create a consensus for treatment pathway for OED.

查看原文本刊更多论文

口腔上皮发育不良：我们有管理解决方案吗？系统回顾

目前，对于口腔上皮发育不良（OED）患者的治疗和随访，还没有明确的批准指南。仅根据上皮发育不良的程度来预测肿瘤的恶性转化潜力和决定治疗方案存在很大的争议。本综述的目的是为OED确定循证管理途径。系统评价使用PubMed、EMBASE和PRISMA指南进行。在应用纳入和排除标准后，只有12项研究被纳入本综述。总体而言，报告的复发率（2.5% - 51.4%）和恶性转化率（MTR）（2.6 - 27%）差异很大。恶性转化的不典型增生程度无统计学意义。主要的治疗方法包括观察、激光消融和切除，但没有具体的治疗证据。因此，迫切需要召开多学科会议，就OED的治疗途径达成共识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Oral and Maxillofacial Surgery

自引率

0.00%

发文量